Spots Global Cancer Trial Database for Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma
Official Title: Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study
Study ID: NCT02103257
Study Description
Brief Summary: This randomised, controlled, multicentre trial is designed to assess the efficacy and safety of sequential icotinib plus chemotherapy versus single icotinib as first-line treatment in stage IIIB/IV lung adenocarcinoma patients with EGFR mutation.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
First Hospital of Lanzhou University, Lanzhou, Gansu, China
Lanzhou military region general hospital, Lanzhou, Gansu, China
General Hospital of Guangzhou Military Command, Guangzhou, Guangdong, China
Cancer Hospital of Sun Yat-sen, Guangzhou, Guangdong, China
First Affiliated Hospital of Guangzhou Medical College, Guangzhou, Guangdong, China
Jiangmen central hospital, Jiangmen, Guangdong, China
The university of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong, China
Shenzhen People's Hospital, Shenzhen, Guangdong, China
Medical Oncology,Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
Thoracic Surgery,Shenzhen Second People's Hospital, Shenzhen, Guangdong, China
Peking University Shenzhen Hospital, Shenzhen, Guangdong, China
Guangdong Agribusiness Center Hospital, Zhanjiang, Guangdong, China
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Hainan Provincal Nong Ken Hospital, Haikou, Hainan, China
Hainan Provincial People's Hospital, Haikou, Hainan, China
First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Medical Oncology，General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
Radiation Oncology，General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
Respiratory medicine，General Hospital of Ningxia Medical University, Yinchuan, Ningxia, China
Baoji Central Hospital, Baoji, Shanxi, China
3201 Hospital, Hanzhong, Shanxi, Hanzhong, Shanxi, China
Shaanxi province people's hospital, Xi'an, Shanxi, China
Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China
Xi'an Chang'an Hospital, Xi'an, Shanxi, China
Tangdu Hospital，Fourth Military Medical University, Xi'an, Shanxi, China
First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shanxi, China
Shanxi Cancer Hospital, Xi'an, Shanxi, China
Urumqi General Hospital of Lanzhou Military Region General Hospital, Urumqi, Xinjiang, China
Xinjiang medical university affiliated tumor hospital, Urumqi, Xinjiang, China
First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China
Autonome Region Xinjiang Uygur Chinese medicine hospital, Urumqi, Xinjiang, China
Contact Details
Name: Helong Zhang, MD
Affiliation: Tang-Du Hospital
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
